A COVID-19 vaccine from BioNTech and Pfizer targeting variants of the Omicron BA.4 and BA.5 subtypes will enter clinical trials this month, and BioNTech expects to begin delivering the vaccine as early as October. Chief Medical Officer Özlem Türeci said data from studies in mice showed that vaccines against BA.4 and BA.5 elicited stronger immune responses. She believes these data, combined with extensive experience and data from previous vaccines, may be sufficient for emergency approval. The highly contagious BA.5 variant has accounted for more than 80 percent of new Covid-19 cases in the U.S. over the past few weeks.
This article is reprinted from: https://www.solidot.org/story?sid=72401
This site is for inclusion only, and the copyright belongs to the original author.